Knowledge Center
Article / Oct 01, 2012
New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit
Source:
Drug Development and Delivery, October 2012
“An issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as ɫAV, that can apply multiple platforms, to increase the probability of solving the problem, and deliver the desired outcome.”
Related links
Also in the Knowledge Center
/ Dec 28, 2016
Continuous production of particles, micro- and/or nanoparticles, particulate amorphous solid dispersions, particulate co-crystals and pharmaceutical compns.
Read more
Scientific Article
/ Oct 23, 2016
Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability
Read more
Scientific Article
/ Aug 30, 2016
Accelerating approval and reducing costs of spray dried drugs through development by design
Read more
Scientific Article